Security key
040334104
Aridis Pharmaceuticals, Inc. - Common Stock (ARDS)
CUSIP: 040334104
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 3,000
- Total 13F value
- $3
- Share change
- +3,000
- SEC-reported price per share
- $0.00
- Number of holders
- 1
- Value change
- +$3
- Number of buys
- 1
- Shares outstanding
- 44,586,623
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
1
Top holders
1
ARDS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q1 2024
Aridis Pharmaceuticals, Inc. SEC filings
Aridis Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 040334104
Recent filing periods:
Ownership snapshot
Top reported holders of ARDS - Aridis Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Cystic Fibrosis Foundation
Disclosed value leader
Vu L. Truong
Comparable rows
0/9
Latest evidence
27 Jun 2024
3/4/5
Highest disclosed value: $96,505
9 rows are not safely comparable across share classes.
Showing 1-6 of 9 holder rows.
Quick read
Vu L. Truong has the largest disclosed position value at $96.5K.
0 of 9 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Vu L. Truong's linked filing trail.
Disclosed position value
Top 2
Vu L. Truong
$96.5K
Eric Patzer
$61.9K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 9 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Cystic Fibrosis Foundation |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
5,168,732 shares
|
— | 08 Dec 2022 |
| Vu L. Truong |
3/4/5
CEO, Director
|
—
mixed-class rows
|
$96,505
2,196,389 shares
mixed-class rows
|
— | 24 Jun 2024 |
| Eric Patzer |
3/4/5
Director
|
—
mixed-class rows
|
$61,922
1,046,462 shares
mixed-class rows
|
— | 24 Jun 2024 |
| Hasan Jafri |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
382,495 shares
|
— | 27 Jun 2024 |
| John F. Hamilton |
3/4/5
Director
|
—
class O/S missing
|
—
269,040 shares
|
— | 27 Jun 2024 |
| Richards Windham Bannister |
3/4/5
Director
|
—
class O/S missing
|
—
261,000 shares
|
— | 27 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
3,000
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q1 2024 Across Filers
Q1 2024 holders
0
Q3 2025 holders
1
Holder diff
1
| Investor | Q1 2024 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q1 2024 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend